The implantable continuous glucose sensor system includes a miniaturized sensor and reader.

The sensor is implanted into the subcutaneous space in the wrist and is inductively powered and remotely interrogated, requiring no battery and no wires connecting the sensor to an external wristwatch-based reader.

The sensor functions noninvasively, automatically, and continuously, after the implantation.

The study incluced 9 subjects with Type 1 diabetes who were implanted with a sensor in each wrist for 29 days.

The performance was assesed using Clarke Error Grid (CEG) analysis where 96.8% were found to beclinically accurate and consistent with the lab reference value.

SMSI CEO and president Tim Goodnow said based on the results obtained, they plan to initiate more clinical trials in the very near future, including pursuing collaboration on artificial pancreas research.